Lipoprotein(a) — Screening, Interpretation & Cascade
Lp(a) is a genetically-determined atherogenic lipoprotein with a causal association with ASCVD. The 2026 guideline makes a Class 1 recommendation to measure Lp(a) at least once in a lifetime in all adults. Elevated Lp(a) functions as a risk enhancer that tips borderline / intermediate patients toward LLT.
Step 1 — Order Lp(a) at least once in every adult's lifetime
Class 1 — Lp(a) measurement at least once in a lifetime in all adults.
Preferred units: nmol/L (particle-based) when available. Mass-based (mg/dL) is acceptable but is a less direct measure.
- Elevated threshold (risk enhancer): ≥125 nmol/L OR ≥50 mg/dL
- Fasting status does not matter — Lp(a) is genetically determined and does not change with fasting
Why "at least once":
- Lp(a) is 70–90% heritable — it is relatively stable across adult life
- A normal Lp(a) once rarely needs repeating
- An elevated Lp(a) is persistent and does not need confirmation / monitoring on serial measurement
- Lp(a) rises in acute inflammation and some pregnancies — defer measurement during acute illness
Step 2 — Interpret the result
| Lp(a) | Interpretation |
|---|
| <75 nmol/L (or <30 mg/dL) | Normal — low ASCVD contribution; no further action for Lp(a) |
| 75–125 nmol/L (or 30–49 mg/dL) | Intermediate — some additional ASCVD risk; use clinical judgement |
| ≥125 nmol/L OR ≥50 mg/dL | Elevated — ACTS AS A RISK ENHANCER per the CPR framework |
| Very high (e.g. >180 nmol/L or >70 mg/dL) | Confers risk comparable to familial hypercholesterolaemia; LLT consideration even in low 10-year ASCVD risk |
Step 3 — Use elevated Lp(a) in the CPR framework
Elevated Lp(a) is a biomarker risk enhancer (per dyslipidemia-cpr-framework-2026). It tips the LLT decision toward treatment in borderline / intermediate PREVENT-ASCVD categories.
Scenarios:
| Patient scenario | Action |
|---|
| Low 10-year risk (<3%), Lp(a) normal | No LLT; lifestyle |
| Low 10-year risk (<3%), Lp(a) very high (e.g. >75 mg/dL / 180 nmol/L) | Consider LLT despite low 10-year risk — Lp(a) confers lifetime risk analogous to FH |
| Borderline (3–<5%), Lp(a) elevated | Enhancer satisfied — favour LLT |
| Intermediate (5–<10%), Lp(a) elevated | Enhancer satisfied — supports LLT intensification |
| High (≥10%), Lp(a) elevated | Already on high-intensity statin; elevated Lp(a) supports aggressive LLT (consider PCSK9i add-on) |
| Any risk category, Lp(a) elevated + concomitant FH | High / very-high risk — treat aggressively with high-intensity statin ± PCSK9i |
Elevated Lp(a) also triggers:
- Cascade screening of first-degree relatives — see Step 4
- Consideration of more aggressive LDL goals
- Shared decision-making about lifelong statin ± non-statin therapy
Step 4 — Cascade screening of first-degree relatives
Cascade screening of first-degree relatives is recommended when the index case has any of:
- Elevated Lp(a) (≥125 nmol/L or ≥50 mg/dL)
- Premature ASCVD (men <55 y, women <65 y)
- Familial hypercholesterolaemia (LDL ≥190 mg/dL in adults, or clinical / genetic diagnosis)
What to screen in relatives:
- Full lipid panel including TC, HDL-C, TG, LDL-C (Martin-Hopkins or Sampson calculation), non-HDL-C
- Lp(a) — once per lifetime per relative
- Genetic testing if presumed FH
Who counts as first-degree: parents, siblings, children ≥9 years of age (universal paediatric lipid screening ages 9–11 captures them anyway)
Step 5 — Lp(a) in children and adolescents
- Universal paediatric lipid screening at ages 9–11 (ADA / NHLBI endorsed) — Lp(a) can be measured as part of this
- Cascade screening of children when a parent has premature ASCVD, FH, or elevated Lp(a) — do the lipid panel including Lp(a) in the child
- After adolescence, screening every 5 years as part of ongoing risk assessment
Early identification allows for lifestyle intervention, cascade screening of second-degree relatives, and age-appropriate LLT discussions in adolescence.
Step 6 — Treatment considerations for elevated Lp(a)
Current reality: there is no approved Lp(a)-specific therapy that has demonstrated outcome benefit.
Options:
- Statins — do NOT significantly lower Lp(a) (may slightly increase in some patients), but still indicated for LDL management given the ASCVD risk conferred by elevated Lp(a)
- PCSK9 inhibitors (alirocumab, evolocumab) — lower Lp(a) by ~20–30%; included in LLT optimisation per LDL goals
- Niacin — lowers Lp(a) ~20–30% but no outcome benefit when added to statin; not recommended for Lp(a)-specific therapy
- Lipoprotein apheresis — reserved for severe elevations with progressive ASCVD; limited availability
- Investigational: antisense oligonucleotides (e.g. pelacarsen) and siRNA (e.g. olpasiran, lepodisiran, zerlasiran) targeting apo(a) — in Phase 3 cardiovascular outcome trials. Not yet approved.
Practical approach:
- Confirm elevated Lp(a) — one measurement is enough
- Aggressively treat conventional lipids — LDL, non-HDL, ApoB to the lowest achievable goals
- Cascade screen relatives (Step 4)
- Lifestyle optimisation — diet, exercise, weight, tobacco
- Shared decision-making — explain that Lp(a) itself does not currently have a specific treatment with proven outcome benefit, but conventional lipid management reduces overall ASCVD risk
- Document elevated Lp(a) in the problem list for future care continuity
Guardrails
- Lp(a) is a lifetime measurement — a normal Lp(a) does not need repeating in a stable patient. Do NOT order it serially
- An elevated Lp(a) does not need confirmation — one measurement is sufficient. Repeat testing of an elevated value is low-yield
- Measure in nmol/L when available — mass units (mg/dL) are affected by apo(a) isoform size and are less reliable for cross-patient comparison
- Defer measurement during acute illness or acute inflammation — Lp(a) rises transiently; wait until stable
- Elevated Lp(a) by itself is not an automatic Class-1 LLT indication — it is a risk enhancer that tips borderline / intermediate decisions. Very high Lp(a) (>75 mg/dL or 180 nmol/L) does strongly favour LLT even in low 10-year risk
- Lp(a) does NOT change with lifestyle — do not promise patients that diet and exercise will lower it. They won't. The purpose of lifestyle advice in the setting of high Lp(a) is lowering OVERALL ASCVD risk
- Statins do not lower Lp(a) meaningfully; sometimes they raise it slightly. Do not avoid statins because of this — they still reduce overall ASCVD risk via LDL
- Niacin is NOT recommended for Lp(a) despite its biochemical effect — no outcome benefit when added to statin
- Cascade screening is often missed — the index case comes in and leaves without triggering family screening. Build this into the workflow at the point of result delivery
- Investigational Lp(a) therapies are promising but NOT yet approved — do not promise patients these drugs are available
- Do not screen Lp(a) more frequently than once unless there is a specific clinical reason (e.g. post-pregnancy restabilisation)
Related MD2SKILL skills
prevent-ascvd-risk-calculator-interpretation — Lp(a) feeds into the risk discussiondyslipidemia-cpr-framework-2026 — Lp(a) is a biomarker risk enhancer in the Personalize stepdyslipidemia-ldl-treatment-goals-2026 — elevated Lp(a) supports more aggressive LDL / non-HDL / ApoB goals
Sources
Primary: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Multisociety Guideline on the Management of Dyslipidaemia.
Review used for extraction: Abramov D et al. Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline. Current Atherosclerosis Reports. 2026;28:63. DOI: 10.1007/s11883-026-01437-9. Section "Key Message 2: Quantification of Dyslipidemia" (Lp(a) Class 1 recommendation and cascade screening).